Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

o PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in a Phase II combination therapy trial for the treatment of advanced breast cancer and additional Phase II trials in non-small cell lung cancer (NSCLC) and breast cancer are expected to begin soon. A Phase I bavituximab monotherapy trial in advanced solid cancers is continuing.

Poster Number: 15G, Abstract No: 3038: R. Digumarti, P.P. Bapsy, J.S. Shan, "A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies." Sunday, June 1, 2008, 2:00 PM - 6:00 PM CDT.

Separately, on Saturday, May 31, 2008 Peregrine issued a press release reporting on its brain cancer drug Cotara(R). The release reviewed dosimetry trial data presented at ASCO confirming a key attribute of Cotara--that it specifically concentrates in brain tumors, leaving healthy tissue in the body largely unaffected. The release also reported that all of the GBM patients treated to date in the Cotara Phase II safety and efficacy trial have survived past the expected median survival time for relapsed GBM patients, an early but encouraging result. The press release can be found at http://ir.peregrineinc.com/releases.cfm

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides deve
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A case ... collaboration between the school,s bioengineering department and the ... the Intel® Software Academic Program, UCSD,s research focuses ... the human body.  Photo - ... exhibits the work of Dr. Todd P. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... YORK, Dec. 10, 2010 Pfizer Inc. (NYSE: ... of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) ... regions where it is approved (the European Union, Canada ... of Thelin worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... University researchers have moved a step closer to ... and hold other advantages over conventional lithium-ion batteries. ... display screens, smart cards, flexible electronics and biomedical ... nickel-tin nanowires perfectly encased in PMMA, a widely ...
... the world,s smallest battery its anode a single ... has been created by a team led by Sandia ... the anode,s characteristics, the tiny rechargeable, lithium-based battery was ... Center for Integrated Nanotechnologies (CINT), a Department of Energy ...
Cached Biology Technology:Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Better batteries from the bottom up 2World's smallest battery created at CINT nanotechnology center 2World's smallest battery created at CINT nanotechnology center 3
(Date:8/20/2014)... Feng has built upon a National Science Foundation (NSF) ... program, and synergistically complemented it with subsequent collaborative grants, ... on "big computing" for mini-drones and a $1 million ... on "big data" for the life sciences. , As ... grant, he was able to tell a much larger, ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
(Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... EAST LANSING, Mich. Nitrous oxide, a potent greenhouse gas, ... century, and nitrogen in waterways is fueling part of that ... on this new study, the role of rivers and streams ... appears to be twice as high as estimated by the ...
... Christmas, BYU nutritionists are squeezing all the healthy compounds out ... their age-old health benefits. , The popular stocking stuffer is ... wanted to learn why a whole orange is better for ... of the research could be a super-supplement that captures the ...
... Fast-moving objects create blurry images in photography, and the ... tissues constantly in motion, such as the breathing lung. ... developed a method to stabilize living lung tissue for ... The method allowed the team to observe, for the ...
Cached Biology News:Waterways contribute to growth of potent greenhouse gas 2The orange in your stocking: researchers squeezing out maximum health benefits 2New imaging advance illuminates immune response in breathing lung 2New imaging advance illuminates immune response in breathing lung 3
... Cell Lab Quantas unique combination of ... population resolution capabilities and accurate cell ... excitation wavelengths, including UV, allowing flexible ... multi-color applications typically only achievable with ...
... 500 Series is a sophisticated ... most advanced technologies available. The ... testing, powerful software and a ... researchers optimize their overall workflow ...
... 250 g monoclonal antibody irreversibly crosslinked ... ~13 g of PDH complex from heart ... bovine heart mitochondria for control immunocapture. ,The ... isolation of PDH from small amounts of ...
... Protein/antibody delivery using PULSin may be ... For example, unlike traditional transfection, with PULSin ... the level and time course of proteins ... may provide more information than traditional RNA ...
Biology Products: